ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
ABSTRACT: 4008 Newswise — CHICAGO ― HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer (BTC), researchers from The University of Texas…
Read more ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer